BBNX: Hopman Mark discloses a sale
By AlphaYouPublished Form 4
Hopman Mark
Reporting filer
Hopman Mark reported Sale in Beta Bionics, Inc.: 370.00 units of Common Stock, dated 2026-10-01. The full Form 4 contains 1 transaction entry.
- Disclosed
- Oct 5, 2026
Reported details
1 entry| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Hopman Mark | 2026-10-01 | S | Sale | 370.00 | 18.96 | 56,109 | 4 days | Filed terms
|
Common Stock
- Owner
- Hopman Mark
- Date
- 2026-10-01
- Code
- S
- Action
- Sale
- Quantity
- 370.00
- Price
- 18.96
- Following holdings
- 56,109
- Reporting delay
- 4 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-10-01
- deemed Execution Date:
- transaction Form Type: 4
- transaction Code: S
- equity Swap Involved: false
- id: F1
- transaction Timeliness:
- transaction Shares: 370.00
- transaction Price Per Share: 18.96
- id: F2
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 56109.00
- direct Or Indirect Ownership: D
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Hopman Mark: Chief Commercial Officer.
- The filing reports a Rule 10b5-1 trading plan.
- F1: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026.
- F2: The weighted average sale price for the transaction reported was $18.96 and the range of prices were between $18.96 and $19.9599. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Original sources
Prepared automatically from public filing data. Report a correction.